Thor Medical ASA: Disclosure of large shareholdings

Oslo, Norway, 15 January 2025: Reference is made to the stock exchange announcement by Thor Medical ASA (the "Company") on 11 December 2024 regarding a private placement of new shares to be issued by the Company (the "Private Placement") and stock exchange announcement by the Company on 6 January 2025 regarding disclosure of share lending.

In connection with the registration of the share capital increase pertaining to tranche 2 ("Tranche 2") of the Private Placement, the manager has redelivered a total of 11,396,380 borrowed shares to Scatec Innovation AS, close associate of primary insider of the Company John Andersen.

During the term of the loan, and prior to the redelivery of the shares, Scatec Innovation AS' shareholding in the Company was reduced to 54,605,876, equivalent to approx. 19.5% of the issued share capital and votes. Upon redelivery of the borrowed shares and delivery of the 12,000,000 new shares allocated to Scatec Innovation AS in Tranche 2, Scatec Innovation AS' holding of shares in the Company is 78,002,256, equivalent to approx. 25.7 % of the issued share capital and votes. Consequently, Scatec Innovation AS has crossed above the 20% and 25% thresholds pursuant to section 4-2 (1) and (3) of the Norwegian Securities Trading Act.

In addition, Scatec Innovation AS has controlling interest in Scatec Invest IV AS, which holds 3,165,920 shares in the Company. Scatec Innovation AS aggregated holding of shares is thus 81,168,176, of which 6,849,880 shares is held by Scatec Innovation AS on behalf of Thorium Foundation as the beneficial owner of the shares, equivalent to approx. 26.7% of the shares and votes in the Company.

This announcement is published in accordance with section 4-2 of the Norwegian Securities Trading Act and is subject to disclosure requirements pursuant to the EU Market Abuse Regulation article 19 (3) and the Norwegian Securities Trading Act section and 5-12.

 

Contacts

Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com

 

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no - https://www.thormedical.no.